MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03703cam a2200409 a 4500 |
| 001 - ACCESSION NUMBER |
|---|
| control field |
10410 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
CUTN |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20160316163510.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION |
|---|
| fixed length control field |
m d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr n |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
110426s2012 flua s 000 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781439813829 (hardback) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(WaSeSS)ssj0000534031 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Transcribing agency |
DLC |
| Modifying agency |
DLC |
| -- |
WaSeSS |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RS431.A64 |
| Item number |
A562 2012 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.99/4061 |
| Edition number |
22 |
| 084 ## - OTHER CLASSIFICATION NUMBER |
|---|
| Classification number |
SCI013000 |
| Source of number |
bisacsh |
| 210 10 - ABBREVIATED TITLE |
|---|
| Abbreviated title |
Anticancer Agents from Natural Products |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Anticancer Agents from Natural Products |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc |
edited by Gordon M. Cragg, David G.I. Kingston, and David J. Newman. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
2nd ed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
Boca Raton : |
| Name of publisher, distributor, etc |
CRC Press, |
| Date of publication, distribution, etc |
c2012. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xv, 751p, |
| Dimensions |
26 cm. |
| 506 ## - RESTRICTIONS ON ACCESS NOTE |
|---|
| Terms governing access |
License restrictions may limit access. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
"This book covers clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. The second edition includes drugs that are currently in development. In addition, the text emphasizes the applications of synthetic and medicinal chemistry to the preparation of analogs with enhanced activities. Contributors also address the potential of novel drug discovery through the use of genome mining as well as the status of advanced development candidates. For each compound of class of compounds, the text provides information on the history, structure, mechanism of action, development, synthesis, medicinal chemistry, and clinical applications"-- |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
"The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"-- |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Antineoplastic agents. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacognosy. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Natural products. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
SCIENCE / Chemistry / General. |
| Source of heading or term |
bisacsh |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Cragg, Gordon M. L. |
| Locally assigned cutter number (editor) |
CRA |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kingston, David G. I. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Newman, David J. |
| 773 #0 - HOST ITEM ENTRY |
|---|
| Title |
CHEMLIBnetBASE |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://www.columbia.edu/cgi-bin/cul/resolve?clio9478719">http://www.columbia.edu/cgi-bin/cul/resolve?clio9478719</a> |
| Public note |
Full text available from CHEMLIBnetBASE |
| 910 ## - USER-OPTION DATA (OCLC) |
|---|
| User-option data |
Library of Congress record |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
General Books |
